tesa Labtec Offers New Licensing Opportunity: Ropivacaine Transdermal Patch for the Treatment of Neuropathic Pain
The German patch and thin-film maker announces the availability of a ropivacaine transdermal patch formulation for the treatment of neuropathic pain.
tesa has developed a matrix patch containing the local anesthetic ropivacaine (3%). The patch is applied directly to the affected area and should deliver long-lasting pain relief for at least 24 hours. The targeted primary indication is post-herpetic neuralgia (PHN). However, additional indications such as other chronic neuralgias, painful non-healing leg ulcers, burn pain, diabetic neuropathy and chronic lower back pain could also be addressed.
Existing market products require a higher dose and can only be worn for 12 hours, resulting in discontinuous treatment. tesa’s product provides a lower dose, which reduces the risk of systemic toxicity and makes application for 24 hours or longer possible. Further patient benefits include gentle patch adhesion, trauma-free removal and no detachment problems.
The contract development and manufacturing organization (CDMO) has filed a PCT application for the product that is intended to protect its innovative formulation approach for the transdermal patch.
tesa is endeavoring to find a product partner in order to continue the development of the patch by accomplishing a proof of concept study and executing a phase II study.
Interested pharmaceutical companies are invited to meet tesa’s representatives at CPHI North America in Philadelphia (May 16-18) or at BIO International in San Diego (June 19-22).
About tesa Labtec
tesa Labtec undertakes the development and manufacture of film-shaped dosage forms (CDMO services) such as transdermal and topical patches as well as oral, buccal or sublingual films. Business activities comprise formulation development, scale-up and manufacture of clinical trial supplies or finished products under full cGMP conditions. tesa relies on its proprietary technologies, Transfilm®, Rapidfilm® and Mucofilm®, for this. tesa Labtec is a wholly owned subsidiary of tesa SE, a member of the Beiersdorf group of companies, and represents the pharmaceutical business in a truly global family of companies.
tesa Labtec GmbH
Director Business Development
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00 | Pressemelding
Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu
World Trade Center Gibraltar: £65m Annual Boost to Local Economy20.10.2017 09:48 | Pressemelding
A report detailing the social and economic impacts of World Trade Center (WTC) Gibraltar was presented to the World Trade Centers Association (WTCA) in New York this week. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005285/en/ Ed Allison-Wright of WTC Gibraltar, with Scott Ferguson, WTCA, New York (Photo: Business Wire) Following the official opening of World Trade Center Gibraltar by the Chief Minister and Deputy Chief Minister in February of this year, World Trade Center Gibraltar commissioned the independent international economic consultancy Nairne Limited, to study and report on the economic contributions of the World Trade Center to the Gibraltar economy. This comes in the midst of an unprecedented take up of the office accommodation within the state-of-the-art facility. An astonishing
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom